We can’t show the full text here under this license.
Abstract
GLP-1 receptor agonists may significantly improve liver conditions in patients with metabolic dysfunction-associated steatotic liver disease (), with up to 62.9% achieving resolution without worsening fibrosis.
- Liraglutide increased steatohepatitis resolution without fibrosis worsening to 39%, compared to 9% with placebo.
- Semaglutide demonstrated dose-dependent resolution of steatohepatitis, reaching up to 59% compared to 17% in Phase 2 trials.
- In interim analyses, semaglutide 2.4 mg weekly met histologic endpoints, achieving 62.9% resolution without fibrosis worsening and 36.8% fibrosis improvement.
- Tirzepatide showed high rates of MASH resolution (44%-62%) and fibrosis improvement signals (up to 51% vs. 30%).
- Cardiovascular outcome trials indicate consistent reductions in major adverse cardiovascular events with GLP-1 receptor agonists.
- GLP-1 receptor agonists may reduce hepatic lipogenesis, improve insulin sensitivity, and have systemic benefits on weight and blood pressure.
Simplified